These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 19222460

  • 1. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.
    Arnold DF, Burton J, Shine B, Wojnarowska F, Misbah SA.
    Br J Dermatol; 2009 May; 160(5):1098-102. PubMed ID: 19222460
    [Abstract] [Full Text] [Related]

  • 2. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
    Engineer L, Bhol KC, Ahmed AR.
    J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.
    Sami N, Bhol KC, Ahmed RA.
    Eur J Dermatol; 2003 Dec; 13(4):377-81. PubMed ID: 12948919
    [Abstract] [Full Text] [Related]

  • 6. The role of IVIg treatment in severe pemphigus vulgaris.
    Baum S, Scope A, Barzilai A, Azizi E, Trau H.
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):548-52. PubMed ID: 16684282
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production.
    Bhol KC, Desai A, Kumari S, Colon JE, Ahmed AR.
    Clin Immunol; 2001 Aug; 100(2):172-80. PubMed ID: 11465946
    [Abstract] [Full Text] [Related]

  • 9. What's new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus.
    Aoyama Y.
    J Dermatol; 2010 Mar; 37(3):239-45. PubMed ID: 20507387
    [Abstract] [Full Text] [Related]

  • 10. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
    Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y.
    Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
    [Abstract] [Full Text] [Related]

  • 11. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
    Ahmed AR.
    J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
    [Abstract] [Full Text] [Related]

  • 12. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
    Segura S, Iranzo P, Martínez-de Pablo I, Mascaró JM, Alsina M, Herrero J, Herrero C.
    J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
    [Abstract] [Full Text] [Related]

  • 13. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.
    Czernik A, Beutner EH, Bystryn JC.
    J Am Acad Dermatol; 2008 May; 58(5):796-801. PubMed ID: 18423257
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N, Qureshi A, Ahmed AR.
    Eur J Dermatol; 2002 May; 12(2):174-8. PubMed ID: 11872417
    [Abstract] [Full Text] [Related]

  • 16. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.
    Mimouni D, Blank M, Ashkenazi L, Milner Y, Frusic-Zlotkin M, Anhalt GJ, David M, Shoenfeld Y.
    Clin Exp Immunol; 2005 Dec; 142(3):426-32. PubMed ID: 16297153
    [Abstract] [Full Text] [Related]

  • 17. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.
    Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A, StreptIg Study Group.
    Clin Infect Dis; 2003 Aug 01; 37(3):333-40. PubMed ID: 12884156
    [Abstract] [Full Text] [Related]

  • 18. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial.
    Mentink LF, Mackenzie MW, Tóth GG, Laseur M, Lambert FP, Veeger NJ, Cianchini G, Pavlovic MD, Jonkman MF.
    Arch Dermatol; 2006 May 01; 142(5):570-6. PubMed ID: 16702494
    [Abstract] [Full Text] [Related]

  • 19. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.
    Green MG, Bystryn JC.
    Arch Dermatol; 2008 Dec 01; 144(12):1621-4. PubMed ID: 19075146
    [Abstract] [Full Text] [Related]

  • 20. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG.
    Aoyama Y, Nagasawa C, Nagai M, Kitajima Y.
    Eur J Dermatol; 2008 Dec 01; 18(5):557-60. PubMed ID: 18693160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.